The impact of patient-perceived restricted access to anti-TNF therapy for rheumatoid arthritis: A qualitative study

Musculoskeletal Care

Volumn 7, Issue 3, 2009, Pages 194-209

  Sanderson, Tessa ^a   Calnan, Michael ^b   Morris, Marianne ^a   Richards, Pam ^c   Hewlett, Sarah ^a  

^a UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Anti TNF; Patient perspective; Qualitative; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; DRUG ANTAGONISM; EMOTION; EMOTIONAL DISORDER; FEMALE; HEALTH CARE DELIVERY; HUMAN; INTERVIEW; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSYCHOLOGICAL ASPECT; RHEUMATOID ARTHRITIS; UNIVERSITY HOSPITAL;

ADULT; AFFECTIVE SYMPTOMS; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EMOTIONS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HOSPITALS, UNIVERSITY; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; PATIENT SATISFACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349413414     PISSN: 14782189     EISSN: 15570681     Source Type: Journal    
DOI: 10.1002/msc.149     Document Type: Article

References (37)

1. Ahlmen M, Nordenskiold U, Archenholtz B, Thyberg I, Rönnqvist R, Lindén L, Andersson A-K, Mannerkorpi K (2005). Rheumatology outcomes: The patient's perspective. A multicentre focus group interview study of Swedish rheumatoid arthritis patients. Rheumatology 44(1): 105-10. DOI: 10.1093/rheumatology/keh412
2. Arthritis Research Campaign (2008). 'Prescription for pain' for thousands of arthritis patients as NICE withdraws treatments from the NHS. Available at http://www.arc.org.uk/news/pressreleases/nice/untitled.asp [Accessed 31 July 2008].
3. Arthritis and Musculoskeletal Alliance (2008). ARMA's statement on NICE's decision on switching anti-TNF for RA. Available at http://www.rheumatology.org.uk/media/pressreleases/news_item.2008-07-18.7982600363 [Accessed 31 July 2008].
4. Baumgartner S, Fleischmann R, Moreland L, Schiff M, Markenson J, Whitmore J (2004). Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. Journal of Rheumatology 31(8): 1532-7.
5. Breedveld F, Emery P, Keystone E, Patel K, Furst D, Kalden D, St Clair E, Weisman M, Smolen J, Lipsky PE, Maini RN (2004). Infliximab in active early rheumatoid arthritis. Annals of the Rheumatic Diseases 63(2): 149-55.
6. Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, Tugwell P, Wells G (2003). Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 4.
7. Blumenauer B, Judd M, Wells G, Burls S, Cranney M, Hochberg M, Tugwell P (2002). Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 3.
8. Buch MH, Emery P (2006). Nonresponse to tumor necrosis factor antagonists - Is there any point in re-treatment? Nature Clinical Practice Rheumatology 2(6): 288-9. DOI: 10.1038/ncprheum0210
9. Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, Kirwan J (2003). Rheumatology outcomes: The patient's perspective. Journal of Rheumatology 30(4): 880-3.
10. Chilton F, Collett R (2008). Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 6(1): 1-14.
11. Dziadzio M, Keat A, Higgens C (2007). Are anti-TNF therapies too good? An audit of patients' compliance. Journal of Clinical Rheumatology 13(5): 296-7.
12. Edwards J (2004). An exploration of patients' experiences of anti-TNF therapy. Musculoskeletal Care 2(1): 40-50.
13. Elder A, Fox K (1992). Thrombolytic treatment for elderly patients. British Medical Journal 305(6858): 846-7.
14. Fries J, Spitz P, Kraines R, Holman H (1980). Measurement of patient outcome in arthritis. Arthritis & Rheumatism 23(2): 137-45.
15. Genovese M, Bathon J, Martin R, Fleischmann R, Tesser J, Schiff M, Keystone EC, Chester Wasko M, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK (2002). Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two year radiological and clinical outcomes. Arthritis & Rheumatism 46(6): 1442-50.DOI: 10.1002/art.10308
16. Gomez-Reino J, Carmona L; BIOBADASER Group (2006). Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period. Arthritis Research & Therapy 8(1): R29.
17. Hewlett S, Carr M, Ryan S (2005). Outcomes generated by patients with rheumatoid arthritis: How important are they? Musculoskeletal Care 3(3): 131-42.
18. Hyrich K, Lunt M, Dixon W, Watson K, Symmons D; BSR Biologics Register (2008). Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 47(7): 1000-5.
19. Kay L, Griffiths I (2006). UK consultant rheumatologists' access to biological agents and view on the BSR Biologics Register. Rheumatology 45(11): 1376-9. DOI: 10.1093/rheumatology/kel333
20. Kaye K, Lu CY, Day R (2006). Can we deny patients expensive drugs? Australian Prescriber 29(6): 146-8.
21. Keystone E. (2006). Switching tumor necrosis factor inhibitors: An opinion. Nature Clinical Practice Rheumatology 2(11): 575-7. DOI: 10.1038/ncprheum0339
22. Lu CY (2007). An examination of systems of access to important high cost medications: A critical analysis of the nationally subsidised scheme of access to tumour necrosis factor inhibitors in Australia [Doctoral thesis]. University of New South Wales.
23. Marshall N, Wilson G, Lapwoth K, Kay L (2004). Patients' perceptions of treatment with anti- TNF therapy for rheumatoid arthritis: A qualitative study. Rheumatology 43: 1034-8.
24. Navarro-Sarabia F, Ariza-Ariza R, Hernandezcruz B, Villannueva I (2005). Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 3.
25. NICE (2007). Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Technology appraisal guidance no. 130. London: NICE.
26. NICE (2008a). Rheumatoid arthritis - Adalimumab, etanercept and infliximab (sequential use): Final appraisal determination. Available at http://www.nice.org.uk/guidance/index.jsp?action =download&o=41284 [Accessed 22 July 2008].
27. NICE (2008b). Appeal Hearing. Advice on adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis after failure of a previous TNF-α inhibitor (sequential use) Available at http://www.nice.org.uk/nicemedia/pdf/RheumatoidArthritisAdalimumabAppealPanelDecision.pdf [Accessed 1 December 2008].
28. NICE (2008c). The management of rheumatoid arthritis in adults: NICE guideline draft for consultation. Available at http://www.nice.org.uk/nicemedia/pdf/RAAdultsDraftNICEGuidelineConsultation.doc [Accessed 30 August 2008].
29. NRAS (2008). 40,000 people with rheumatoid arthritis to be denied access to life changing drugs. Available at http://www.rheumatoid.org.uk/article.php?article_id=535 [Accessed July 31 2008].
30. PN News (2005). Patients denied access to anti-TNF alpha therapies. Practice Nurse 29(12): 9.
31. Ritchie J, Lewis J (Eds) (2003). Qualitative Research Practice: A Guide for Social Science Students and Researchers. London: SAGE.
32. Strauss A, Corbin J (2003). Grounded Theory methodology: An overview. In Denzin N, Lincoln Y (Eds) Strategies of Qualitative Inquiry. London: Sage.
33. Subrahmanyam P, Gendi N, Dasgupta B (2008). Lack of efficacy of first anti-TNF agent is more likely to result in successful switch to second anti-TNF agent. Rheumatology 47 (Suppl. 2): i30.
34. Van der Heijde D, Hof M, Piet L, Putte L (1993). Development of a disease activity score based on judgement in clinical practice by rheumatologists. Journal of Rheumatology 20(3): 579-81.
35. Van Uden-Kran C, Taal E, Shaw B, Seydel E, van de Laar M (2008). Empowering processes and outcomes of participation in online support groups for patients with breast cancer, arthritis, or fibromyalgia. Qualitative Health Research 18(3): 405-17.
36. Varekamp I, Krol L, Danse J (1998). Age rationing for renal transplantation? The role of age in decisions regarding scarce life extending medical resources. Social Science & Medicine 47 (1): 113-20.
37. Villeneuve E, Haraoui B (2006). Switching between TNF-alpha inhibitors in the treatment of rheumatoid arthritis. International Journal of Advances in Rheumatology 4: 2-8.